Epithelial tissue hyperplasia induced by the RAF inhibitor PF-04880594 is attenuated by a clinically well-tolerated dose of the MEK inhibitor PD-0325901

Molecular Cancer Therapeutics

Volumn 11, Issue 10, 2012, Pages 2274-2283

  Torti, Vince R ^a   Wojciechowicz, Donald ^a   Hu, Wenyue ^a   John Baptiste, Annette ^a   Evering, Winston ^a   Troche, Gabriel ^a   Marroquin, Lisa D ^a   Smeal, Tod ^a   Yamazaki, Shinji ^b   Palmer, Cynthia L ^a   Burns Naas, Leigh Ann ^a,c   Bagrodia, Shubha ^a  

^a PFIZER INC   (United States)

^b Efficacy Dept R D NeoPharm I   (United States)

^c GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PF 04880594; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAF PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN HL 60; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIMERIZATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EPITHELIUM; EPITHELIUM HYPERPLASIA; FLUSHING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN VITRO STUDY; KERATINOCYTE; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; BENZAMIDES; DIPHENYLAMINE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMIS; EPITHELIUM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HL-60 CELLS; HUMANS; HYPERPLASIA; INTERLEUKIN-8; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MODELS, BIOLOGICAL; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; PYRAZOLES; PYRIMIDINES;

EID: 84867429545     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0984     Document Type: Article

References (34)

1. Davies H, Bignell GR, Cox C, Stephens P, Clegg S, Teague J, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54. (Pubitemid 34716871)
2. Rodolfo M, Daniotti M, Vallacchi V. Genetic progression of metatastic melanoma. Cancer Lett 2004;214:133-47.
3. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, et al. B-RAF is a therapeutic target in melanoma. Oncogene 2004;23:6292-8. (Pubitemid 39215299)
4. Chapman PB, Hauschild A, Robert C, Haanen JB, Scierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
5. Krishnamurty R, Maly DJ. Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors. ACS Chem Biol 2010;5:121-38.
6. Aplin AE, Kaplan FM, Shao Y. Mechanisms of resistance to RAF inhibitors in melanoma. J Invest Dermatol 2011;131:1817-20.
7. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature 2010:468:973-7.
8. Carnahan J, Beltran PJ, Babij C, Le Q, Rose MJ, Vonderfecht S, et al. Selective and potent RAF inhibitors paradoxically stimulate normal cell proliferation and tumor growth. Mol Cancer Ther 2010;9:2399-410.
9. Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600EBRAF selective manner. Proc Natl Acad Sci U S A 2010;107:14903-8.
10. Cichowski K, Jänne PA. Inhibitors that activate. Nature 2010;464:358-9.
11. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010;140:209-21.
12. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimmers and ERK signaling in cells with wild type BRAF. Nature 2010;464:427-31.
13. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. Raf inhibitors prime wild-type Raf to activate the MAPK pathway and enhance growth. Nature 2010;464:431-5.
14. Yeh JJ, Routh ED, Rubinas T, Peacock J, Martin TD, Shen XJ, et al. KRAS/BRAF mutation status and ERK 1/2 activation as biomarkers for MEK 1/2 inhibitor therapy in colorectal cancer. Mol Can Ther 2009;8:834-43.
15. Wisler JA, Afshari C, Fielden M, Zimmermann C, Taylor S, Carnahan J, et al. Raf inhibition causes extensive multiple tissue hyperplasia and urinary bladder neoplasia in rat. Toxicol Path 2011;39:809-22.
16. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439:358-62. (Pubitemid 43128863)
17. LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Malburg L, Chapman PB, et al. Phase I pharmacokinetic and pharmacodynamic study of oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 2010;16:1924-37.
18. Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2010;16:2450-7.
19. Boasberg PD, Redfern CH, Daniels GA, Bodkin D, Garrett CR, Ricart AD. Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. Cancer Chemother Pharmacol 2011;68:547-52.
20. Palmer C, Cui J, Deal J, Gu D, Guo C, Kephart S, et al. Discovery of potent, selective inhibitors of mutant B-Raf. (Abstract # MEDI-251). Abstracts of Papers, 242nd ACS National Meeting & Exposition 2011.
21. Wang X, Berger DM, Salaski EJ, Torres N, Dutia M, Hanna C, et al. Indazolylpyrazolopyrimidine as highly potent B-Raf inhibitors with in vivo activity. J Med Chem 2010;53:7874-8
22. NIH guide for the care and use of laboratory animals. NIH Publication 2005 No. 85-23, U.S. Department of Health, Education and Welfare.
23. Huberman E, Callaham MF. Induction of terminal differentiation in human promyelocytic leukemia cells by tumor-promoting agents. Proc Natl Acad Sci U S A 1979;76:1293-7 (Pubitemid 9143726)
24. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
25. Kefford R, Arkenau H, Brown MP, Millward M, Infante JR, Long GV, et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010;28:15s. Abstr #8503.
26. Arnault JP, Wechsler J, Escudier B, Spatz A, Tomasic G, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009;27:e59-61.
27. Robert C, Arnault JP, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol 2011;23:177-82.
28. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008;14:6735-41.
29. Liang S, Sharma A, Peng HH, Robertson G, Dong C. Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation. Cancer Res 2007;67:5814-20. (Pubitemid 46985015)
30. Crawford S, Belajic D, Wei J, Riley JP, Dunford PJ, Bembenek S, et al. A novel B-RAF inhibitor blocks interleukin-8 synthesis in human melanoma xenografts, revealing IL-8 as a potential pharmacodynamic marker. Mol Cancer Ther 2008;7:492-9. (Pubitemid 351482132)
31. Van Kilsdonk JW, Bergers M, Van Kempen LC, Schalkwijk J, Swart GW. Keratinocytes drive melanoma invasion in a reconstructed skin model. Melanoma Res 2010;20:372-80.
32. Infante JR, Falchook DP, Lawrence DP, Weber JS, Kefford RF, Bendell JC, et al. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). J Clin Oncol. 2011;29(suppl: Abstract CRA8503).
33. V600EB-RAF inhibition. Cancer Res 2011;71;5067-74.
34. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011;29:3085-96.